Imvaria is a health tech company focused on AI-driven digital biomarkers for pulmonology. Based in Berkeley, California, it develops non-invasive diagnostic and prognostic biomarkers to aid clinicians in diagnosing interstitial lung diseases and lung fibrosis earlier, while also partnering with biopharmaceuticals for trial optimization and biomarker discovery. The company emphasizes easy adoption through centralized services without heavy integration, and has produced FDA-authorized tools for IPF/ILD such as Fibresolve and ScreenDx. Through collaborations with academic and medical partners, Imvaria aims to improve patient outcomes by enhancing diagnostic accuracy and reducing the need for invasive biopsies.